Business Context and Reporting Period
This Form 8-K Current Report was filed by OncoCyte Corporation (trading symbol: OCX) on May 18, 2021. The filing reports the appointment of a new senior executive officer effective May 18, 2021. The registrant is incorporated in California and its common stock is listed on the NYSE American.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Li Yu as Vice President, Controller, and Principal Accounting Officer. This appointment replaces prior leadership in the accounting function and introduces new compensation arrangements.
Management Commentary and Compensation Details
Ms. Yu brings over 20 years of accounting experience, including roles at Acacia Research Corporation, Key Data Systems, Inc., and Lantronix, Inc. Her compensation package includes:
- Base Salary: $250,000 annually.
- Discretionary Bonus: Target of 35% of base salary based on personal and corporate performance goals.
- Sign-on Equity: 25,000 restricted stock units (RSUs).
- Performance Equity: Up to 15,000 additional RSUs contingent on achieving three specific milestones (streamlining monthly accounting, filing reports under the new process, and streamlining budget/reporting processes). Each milestone awards 5,000 RSUs.
- Stock Options: 160,000 stock options, subject to shareholder approval of an increase in shares available under the 2018 Equity Incentive Plan.
- Vesting: 25% after one year of service; the remainder vests in 36 equal monthly installments starting on the first anniversary.
- Exercise Price: Fair market value at the date of grant.
- Expiration: 10 years from the grant date.
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ from anticipated results due to risk factors detailed in the company's 10-K and 10-Q filings.
Investor Verification Checklist
- Verify whether shareholders have approved the increase in shares available under the 2018 Equity Incentive Plan, as the 160,000 stock options are contingent on this approval.
- Review the specific performance milestones for the 15,000 potential RSUs to assess the likelihood of payout.
- Confirm the fair market value of the stock on the grant date to determine the exercise price of the options.
- Check subsequent filings for any updates to the "Risk Factors" section referenced in the forward-looking statements.